Literature DB >> 2860506

Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788)

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2860506

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  20 in total

Review 1.  Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

Authors:  E A Jones; A S Basile
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Endogenous GABAergic modulators in the pathogenesis of hepatic encephalopathy.

Authors:  J D Rothstein; M Olasmaa
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

3.  Endozepine-4 levels are increased in hepatic coma.

Authors:  Giulia Malaguarnera; Marco Vacante; Filippo Drago; Gaetano Bertino; Massimo Motta; Maria Giordano; Michele Malaguarnera
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

4.  Neuroactive amino acids in hepatic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1996-06       Impact factor: 3.584

Review 5.  The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 6.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 7.  Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy.

Authors:  M Baraldi; R Avallone; L Corsi; I Venturini; C Baraldi; M L Zeneroli
Journal:  Metab Brain Dis       Date:  2008-12-11       Impact factor: 3.584

8.  Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake.

Authors:  P Perney; R F Butterworth; D D Mousseau; J Lavoie; P Fabbro-Peray; F Blanc; G P Layrargues
Journal:  Metab Brain Dis       Date:  1998-09       Impact factor: 3.584

9.  Lack of effect of the benzodiazepine antagonist flumazenil (Ro 15-1788) on the performance of healthy subjects during experimentally induced ethanol intoxication.

Authors:  A Flückiger; D Hartmann; B Leishman; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Flumazenil in the treatment of portal systemic encephalopathy--an overview.

Authors:  K Gyr; R Meier
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.